Unichem Laboratories Ltd

506690

Overview

    • Equity Style Box

      Small Growth

    • Sector

      Healthcare

    • Industry

      Drug Manufacturers - Specialty & Generic

    • Day Range

      595.95 – 609.15

    • Year Range

      507.20 – 949.85

    • Market Cap

      42.1801 Bil

    • Volume / Avg

      582.0 / 3.8 k

    • Price / Sales

      2.00

    • Price / Book

      1.72

    • Price / Earnings

      30.77

    • Forward Div Yield

      0.00%

    • Trailing Div Yield

      —

Login To Show Full Chart

Summary

Fair Value Assessment
Undervalued (8% Discount)
Fair ValueQ657.26UncertaintyHigh
Close Price599.10May 30, 2025
Market Closed
₹ 599.10
Price Down by 4.15 | 0.69 %
Trading Information Business Description
Previous Close
599.10
Day Range
595.95 – 609.15
Year Range
507.20 – 949.85
Bid / Ask
—
Market Cap
42.2 Bil
Volume / Average
582.0 / 3.8 k
Beta (5-Year)
–
Shares Outstanding
70.41 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a global market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
Contact
Off. S. V. Road Unichem Bhavan, Prabhat Estate, Mumbai, MH 400 102
T +91 2266888333
www.unichemlabs.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Mar 31, 2025
Fiscal Year End
Mar 31, 2025
Employees
2,153
As of Mar 31, 2024

Key Metrics

Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Income Statement (in Bil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Revenue
21.11 21.11 16.57 13.02 12.48 11.90
Revenue Growth %
18.25% 18.25% 27.26% 4.36% 4.88% 13.37%
Gross Profit
12.47 12.47 9.73 7.32 8.07 7.89
Gross Profit Margin %
59.09% 59.09% 58.68% 56.21% 64.70% 66.27%
Operating Income
1.40 1.40 -0.13 -1.56 -0.11 0.07
Operating Margin %
6.65% 6.65% -0.78% -11.95% -0.87% 0.61%
EBIT
1.76 1.76 -0.40 -1.61 0.21 0.33
EBIT Margin %
8.32% 8.32% -2.42% -12.33% 1.64% 2.77%
EBITDA
3.00 3.00 0.73 -0.47 1.12 1.17
EBITDA Margin %
14.22% 14.22% 4.41% -3.62% 8.95% 9.86%
Net Income
1.38 1.38 -0.70 -2.02 0.33 0.34
Net Profit Margin %
6.51% 6.51% -4.25% -15.53% 2.65% 2.88%
Basic EPS
19.53 19.53 -10.01 -28.72 4.70 4.88
Diluted EPS
19.47 19.47 -10.01 -28.72 4.68 4.88
Normalized EPS
— — — — — —
Total Dividends per Share
— — — 4.00 4.00 4.00
Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Balance Sheet (in Bil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Total Assets
35.69 35.69 31.69 31.93 33.19 31.26
Total Liabilities
11.19 11.19 8.07 7.58 7.00 5.69
Total Debt
4.60 4.60 2.48 3.14 3.49 1.19
Total Equity
24.51 24.51 23.62 24.35 26.18 25.57
Cash And Cash Equivalents
0.90 0.90 1.51 1.84 1.09 0.77
Working Capital
10.38 10.38 9.86 9.49 10.93 8.72
Shares Outstanding (Mil)
— — — — — —
Book Value Per Share
348.07 348.07 335.11 344.18 370.39 362.06
Total Debt To Equity
0.19 0.19 0.10 0.13 0.13 0.05
Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Cash Flow Statement (in Bil, except ratios)
03/31/2025
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
-0.07 0.17 -0.85 -2.60 0.33 0.20
Cash From Investing Activities
-2.41 0.50 2.03 1.00 -0.74 -0.41
Cash From Financing Activities
1.84 -1.06 -0.81 1.91 -1.21 -0.62
Capital Expenditures
1.37 0.23 0.44 1.27 2.88 3.86
Free Cash Flow
1.30 0.75 -1.16 -0.37 -1.89 -4.27
Change in Cash
-0.64 -0.39 0.36 0.32 -1.62 -0.84

Profile

There is no Key Executive Team data available.
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
Oops!
Something went wrong.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
Oops!
Something went wrong.

Ownership

Ownership lists the Fund owners and Intitutional owners of the stock.
Name
Morningstar
Rating
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Current Shares
Change Amount
Change %
Date
HDFC Small Cap Gr 7.77 1.07 5,473,134
0
0.00%
Apr 30, 2025
DSP Healthcare Fund Reg Gr Not Rated 1.21 1.76 852,063
8,205
0.97%
Apr 30, 2025
ICICI Pru Pharma Healthcare Diag Gr Not Rated 0.34 0.27 241,030
-5,075
2.06%
Apr 30, 2025
DFA Emerging Markets Core Equity 2 I 0.28 0.01 194,087
0
0.00%
Apr 30, 2025
Franklin India Opportunities Gr Not Rated 0.24 0.15 166,436
-165,436
49.85%
Apr 30, 2025
Total (for Top 5) 9.84 6,926,750
-162,306
More Ownership Data

STOCKS
MUTUAL FUNDS
ADITYABIRLAAXISBajajBANDHANBARODABNPBOICANARADSPEDELWEISSFRANKLINTEMPLETONGROWWHDFCHELIOSHSBCICICIIIFLINVESCOITIJMKOTAKLICMahindraManulifeMIRAEMOTILALNAVINipponNJOldBridgePGIMPPFASQUANTQUANTUMSAMCOSBISHRIRAMSUNDARAMTATATAURUSTrustUNIONUTIWhiteOakZERODHA
INSURANCE FUNDS
ABSLAEGONAGEASFEDERALAVIVABAJAJALLIANZBHARTIAXACANARAHSBCORIENTBANKEDELWEISSTOKIOEXIDEFUTUREGENERALIHDFCICICIPRUDENTIALINDIAFIRSTKOTAKMAHINDRALICMAXLIFEPNBMETLIFEPRAMERICARELIANCENIPPONSAHARASBISHRIRAMSTARUNIONDAI-ICHITATAAIA

About Us

Connect With Us

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top